NASDAQ:AEGR - Aegerion Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.97 0.00 (0.00 %) (As of 05/21/2019 01:00 AM ET)Previous Close$1.97Today's Range$1.97 - $1.9752-Week Range$1.23 - $10.85VolumeN/AAverage Volume635,262 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT). Receive AEGR News and Ratings via Email Sign-up to receive the latest news and ratings for AEGR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:AEGR Previous Symbol CUSIP00767E10 CIK1338042 Webwww.aegerion.com Phone+1-617-5007867Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Aegerion Pharmaceuticals (NASDAQ:AEGR) Frequently Asked Questions What is Aegerion Pharmaceuticals' stock symbol? Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR." How were Aegerion Pharmaceuticals' earnings last quarter? Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) released its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.58) by $1.14. The biopharmaceutical company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $43 million. The firm's quarterly revenue was down 39.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.55) earnings per share. View Aegerion Pharmaceuticals' Earnings History. Has Aegerion Pharmaceuticals been receiving favorable news coverage? News articles about AEGR stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aegerion Pharmaceuticals earned a news impact score of -1.6 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. What other stocks do shareholders of Aegerion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aegerion Pharmaceuticals investors own include Allergan (AGN), BioMarin Pharmaceutical (BMRN), Netflix (NFLX), Ariad Pharmaceuticals (ARIA), Arrowhead Pharmaceuticals (ARWR), Celgene (CELG), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO) and Tesla (TSLA). How do I buy shares of Aegerion Pharmaceuticals? Shares of AEGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aegerion Pharmaceuticals' stock price today? One share of AEGR stock can currently be purchased for approximately $1.97. What is Aegerion Pharmaceuticals' official website? The official website for Aegerion Pharmaceuticals is http://www.aegerion.com. How can I contact Aegerion Pharmaceuticals? Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867. MarketBeat Community Rating for Aegerion Pharmaceuticals (NASDAQ AEGR)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 356 (Vote Outperform)Underperform Votes: 288 (Vote Underperform)Total Votes: 644MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe AEGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEGR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Derivative Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.